World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections)
Kalorama Information
February 1, 2012 220 Pages - SKU: KLI6772957
|
|
Countries covered: Global
This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment: (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)
Antibacterials (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)
Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals)
The report covers both currently marketed and late stage development products. Revenues for each segment were generated using dollar and unit sales for each product.
A novel approach in this report is that it provides revenue by product type but also the 'market' for treatments by type of infection, enabling marketers to research the best markets where a variety of products may be implemented.
The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers.
The area of anti-infectives represents an exciting frontier for development of potential life-saving products. However, there are a number of issues and trends that have a direct influence on this market and manufacturers' ability to successfully operate in the market. The issues and trends affecting this market include:
- Drug Resistance
- HIV Trends, Cost, and Access to Drug Therapy
- Other Immunocompromised Population Issues
- Alliances and Partnerships
- New Developments
- Rx-to-OTC Switches
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals focused on the anti-infective industry. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year for data was 2011. Historical data was provided for the years 2007 through 2010, with forecast data provided for 2012 through 2015. Compound annual growth rates (CAGRs) are provided for the 2007-2011, 2011-2015 and 2007-2015 periods for each industry segment covered. Competitive analysis is provided for the years 2007 through 2011 with a special focus on 2011. The forecasted market analysis for 2011-2015 was based on probability of approval and sales of products in late stage development, future trends in current product demand, generic penetration, product marketing, and relevant demographic trends.
Companies profiled in this report include:
- Abbott Laboratories
- Astellas
- AstraZeneca
- Bayer
- Bristol-Myers Squibb
- Cubist
- Daiichi Sankyo
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- Novartis
- Pfizer
- Roche
|
Additional InformationGilead Leads Antiviral Therapy Sales: Kalorama
With combined sales from the top HIV treatment on the market and several other drugs, Gilead Sciences leads the antiviral market, according to healthcare market research publisher Kalorama Information, closely followed by Bristol-Myers Squibb, Roche and Merck. Led by growth in antivirals, the market for all anti-infectives reached $53 billion in 2011, according to Kalorama Information's new report, World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals).
Atripla is the company's newest antiviral product, launched in July 2006, and it's the leading treatment for HIV. It is a nucleoside analog, part of a highly active antiretroviral therapy (HAART) regimen or "cocktail" that under best conditions can reduce the presence of HIV RNA in the patient's plasma to undetectable levels, thus prolonging survival. Kalorama estimated the product's sales to be $3.2 billion in 2011. Truvada, Viread, Hepsera are the company's other antiviral drugs. However, the report finds this is a highly competitive market and other brands are competing for market leadership.
"Gilead Sciences will likely remain strong in the market, but other companies are gaining," said Melissa Elder, the report's author. "Baraclude, for instance, has quadrupled in revenues in the past four years."
Bristol-Myers Squibb holds second place in the antiviral drug market, according to Kalorama Information. The company's Baraclude nucleoside analog has grown from $257 million in sales in 2007 to $1.1 billion today. The company's other leading antiviral drugs are Sustiva and Reyataz. Roche holds the third market position overall; the company's key antivirals include Pegasys, Valcyte, and Tamiflu.
GlaxoSmithKline alone accounted for 25% of the antiviral market in 2009, but has since declined due to patent expirations on key products. The company is not inactive, however. In November 2009, GlaxoSmithKline and Pfizer launched ViiV Healthcare, a new company focusing on HIV treatment that combines the strength of both companies' product and development pipelines in the HIV treatment area. For 2011, the new company accounted for one tenth of the antiviral drug market, according to Kalorama.
Of all the anti-infective drug markets that Kalorama has researched in its report, antivirals presented the most growth and competitive activity. This trend is expected to continue for 2011 with half year sales for key products already showing similar increases. Kalorama's report, World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals), contains more segment market estimates, estimates for revenues by infection treated, and profiles of key companies in the market.
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Total Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
- Overview
- Introduction to Pathogens
- Demographics of the World
- Infections and Drug Resistance
- Causes of Drug Resistance
- Drug Resistance in Select Populations
- Measures for Reducing Resistance
- HIV Trends
- Manufacturer and Marketer Trends
- Trends in Partnerships and Alliances
- Developers Trends
- Aradigm
- ARD-3100
- Phase II
- Cystic fibrosis
- ARD-3150
- Phase II
- Bronchiectasis
- ARD-1100
- Preclinical
- Inhalation anthrax
- Trends in Rx-to-OTC Switches
CHAPTER THREE: ANTIFUNGAL DRUGS
- Overview
- Types of Fungal Infections
- Superficial
- Systemic
- General Fungal Infection Statistics
- Fungal Infection Risk
- Description of Antifungal Products
- Systemic Antifungals
- Topical Antifungals
- Market Overview
- Total Market Size and Forecast
- Antifungal Market by Product Type
- Antifungal Market by Geographical Region
- Market Analysis by Treated Condition
- Competitive Analysis
CHAPTER FOUR: ANTIBACTERIAL DRUGS
- Overview
- Classification of Antibacterial Organisms
- Antimicrobial Spectrum
- Bacterial Resistance
- Principles of Anti-bacterial Therapy
- Combination Therapy and Prophylactic Use
- Bacterial Infection Statistics
- Bacterial Infection Risk
- Classifications of Antibacterial Products
- Aminoglycosides
- Carbapenems
- Cephalosporins
- Macrolides
- Penicillins
- Quinolones
- Sulfonamides
- Tetracyclines
- Market Overview
- Total Market Size and Forecast
- Antibacterial Market by Product Type
- Antibacterial Market by Geographical Region
- Market Analysis by Treated Condition
- Competitive Analysis
- Leading Products
CHAPTER FIVE: ANTIVIRAL DRUGS
- Overview: Introduction to Viruses
- Examples of Pathogenic Viruses
- Virus Function and Life History
- Replication in DNA Viruses
- Replication of RNA Viruses
- Replication in Retroviruses
- Host Defenses Against Viruses 8
- Viral Ploys to Invade Host Cells and Circumvent Host Responses
- Invasion of Host Cells
- Subversion of the Immune Response
- Avoidance of Immune Detection and Attack by Killer Cells
- HIV and AIDS
- Viral Infection Statistics
- Description of Antivirals Products
- Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors
- Protease Inhibitors
- Other Antivirals
- Market Overview
- Total Market Size and Forecast
- Antiviral Market by Product Type
- Antiviral Market by Geographical Region
- Market Analysis by Treated Condition
- Competitive Analysis
CHAPTER SIX: MARKET SUMMARY
- Market by Product Segment (Antifungals, Antibacterials, Antivirals)
CHAPTER SEVEN: CORPORATE PROFILES
- Introduction
- Abbott Laboratories
- Astellas
- AstraZeneca
- Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma)
- Bristol-Myers Squibb
- Cubist
- Daiichi Sankyo
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- Novartis
- Pfizer
- Roche
APPENDIX: COMPANY DIRECTORY
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY -
Table 1-1: The Global Market for Anti-Infectives by Product Segment, 2007-2015
-
Figure 1-1: The Global Market for Anti-Infectives by Product Segment, 2011
-
Figure 1-2: World Market for Anti-Infectives Estimated Market Share of
Leading Suppliers, 2011
CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS -
Table 2-1: World Population by Selected Geographical Region, 2010 - 2050
-
Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2009
-
Figure 2-2: Average Life Expectancy in Years by Country 1980 and 2009
-
Table 2-3: Worldwide HIV/AIDS Infections
-
Table 2-4: Women Living with HIV/AIDS, by Region 2001 to 2009, Number
-
Table 2-5: Antiretroviral Access for HIV Infected Individuals in Low- and
Middle-Income Countries, 2009 based on 2010 WHO Guidelines
-
Table 2-6: Antiretroviral Access for HIV Infected Individuals in Low- and Middle-Income Countries, by Selected Countries, 2009 based on 2010 WHO Guidelines
-
Table 2-7: Anti-Infective Drugs in Development by Developer
-
Table 2-8: Anti-infectives Ingredients Transferred from Rx-to-OTC Status
-
Figure 2-3: Anti-infectives Ingredients Transferred from Rx-to-OTC by Year
CHAPTER THREE: ANTIFUNGAL DRUGS -
Table 3-1: Incidence of Infections by Type, 2010
-
Figure 3-1: Incidence of Infections by Type, 2010
-
Table 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic
Diseases by Selected Geographical Region, 2010
-
Figure 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic
Diseases by Selected Geographical Region, 2010
-
Table 3-3: Treatment Options for Fungal Infections , (Type, Brand, and Manufacturer)
-
Table 3-4: The World Market for Antifungal Drugs 2007-2015
-
Figure 3-3: The World Market for Antifungal Drugs 2007-2015
-
Table 3-5: Antifungal Drug Market by Type 2007-2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)
-
Figure 3-4: The World Market for Antifungal Drugs Revenues by Type 2007-2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)
-
Figure 3-5: The World Market for Antifungal Drugs Revenues by Type 2011 and 2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)
-
Table 3-6: The World Market for Antifungal Drugs Estimated Products
Sales by Geographic Region 2007-2015
-
Figure 3-6: The World Market for Antifungal Drugs Estimated Product Sales
by Geographic Region 2007-2015
-
Table 3-7: World Antifungal Market Estimated Products Sales by Infection Type , (Candida Infections,
Seborrheic Dermatitis,
Onychomycosis, Other Infections)
-
-
Figure 3-7: World Antifungal Market Estimated Distribution of Products Sales
by Infection Type, 2011 Candida Infections,
Seborrheic Dermatitis,
Onychomycosis, Other Infections)
-
Table 3-8: World Market for Antifungal Drugs Estimated Revenues and Market Share of Leading Suppliers 2007-2011
-
Figure 3-8: World Market for Antifungal Drugs Estimated Revenues of Leading
Suppliers, 5-year Comparison 2007-2011
-
Figure 3-9: World Market for Antifungal Drugs Estimated Market Share of
Leading Suppliers, 2011
-
Table 3-9: World Market for Antifungal Drugs Estimated Sales of
Select Products 2007-2011
-
Figure 3-10: World Market for Antifungal Drugs Estimated Sales of
Select Products 2007-2011
CHAPTER FOUR: ANTIBACTERIAL DRUGS -
Table 4-1: Antibiotics with Difficult Penetration
-
Table 4-2: Estimated World and U.S. Incidence of Bacterial Infections, 2010
-
Figure 4-1: Estimated World and U.S. Incidence of Bacterial Infections
-
Table 4-3: World Population at Risk for Serious Bacterial Infections,
Secondary to Chronic Diseases by Selected Geographical Region, 2010
-
Figure 4-2: World Population at Risk for Serious Bacterial Infections,
Secondary to Chronic Diseases by Selected Geographical Region, 2010
-
Table 4-4: Treatment Options for Bacterial Infections , (Type,
Brand, and Manufacturer)
-
Table 4-5: The World Market for Antibacterial Drugs 2007-2015
-
Figure 4-3: The World Market for Antibacterial Drugs 2007-2015
-
Table 4-6: Antibacterial Drug Market by Type 2007-2015
-
Figure 4-4: The World Market for Antibacterial Drugs Revenues by Type, 2007-2015 , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)
-
Figure 4-5: The World Market for Antibacterial Drugs Revenues by Type 2011 and 2015 , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)
-
Table 4-7: The World Market for Antibacterial Drugs Estimated Products
Sales by Geographic Region 2007-2015
-
Figure 4-6: The World Market for Antibacterial Drugs Estimated Product Sales
by Geographic Region 2007-2015
-
Table 4-8: World Antibacterial Market Estimated Products Sales by Infection Type , (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections
Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections)
-
Figure 4-7: World Antibacterial Market Estimated Distribution of Products
Sales by Infection Type, 2011 , (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections
Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections)
-
Table 4-9: World Market for Antibacterial Drugs Estimated Revenues and
Market Share of Leading Suppliers 2007-2011
-
Figure 4-8: World Market for Antibacterial Drugs Estimated Revenues of Leading
Suppliers 2007-2011
-
Figure 4-9: World Market for Antibacterial Drugs Estimated Market Share of Leading Suppliers, 2011
-
Table 4-10: World Market for Antibacterial Drugs Estimated Sales of Select
Products 2007-2011
CHAPTER FIVE: ANTIVIRAL DRUGS -
Table 5-1: Host Cell Receptors
-
Table 5-2: Estimated World and U.S. Incidence of Viral Infections, 2010
-
Figure 5-1: Estimated World and U.S. Incidence of Leading Viral Infections
-
Table 5-3: Treatment Options for Viral Infections , (Type, Brand, and Manufacturer)
-
Table 5-4: The World Market for Antiviral Drugs 2007-2015
-
Figure 5-2: The World Market for Antiviral Drugs 2007-2015
-
Table 5-5: Antiviral Drug Market by Type (HIV, Hepatitis and Other Infections) 2007-2015
-
Figure 5-3: The World Market for Antiviral Drugs Revenues by Type , (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2007-2015
-
Figure 5-4: The World Market for Antiviral Drugs Revenues by Type , (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2011 and 2015
-
Table 5-6: The World Market for Antiviral Drugs Estimated Products
Sales by Geographic Region 2007-2015
-
Figure 5-5: The World Market for Antiviral Drugs Estimated Product
Sales by Geographic Region 2007-2015
-
Table 5-7: World Antiviral Market Estimated Products Sales
by Infection Type (HIV, Hepatitis, Other Infections, Total)
-
Figure 5-6: World Antiviral Market Estimated Distribution of Products
Sales by Infection Type, 2011 (HIV, Hepatitis, Other Infections, Total)
-
Table 5-8: World Market for Antiviral Drugs Estimated Revenues
and Market Share of Leading Suppliers 2006-2009
-
Figure 5-7: World Market for Antiviral Drugs Estimated Revenues of
Leading Suppliers 2007-2011
-
Figure 5-8: World Market for Antiviral Drugs Estimated Market Share of
Leading Suppliers, 2011
-
Table 5-9: World Market for Antiviral Drugs Estimated Sales
of Top Products 2007-2011
-
Figure 5-9: World Market for Antiviral Drugs Estimated Sales of
Top Products 2007-2011
CHAPTER SIX: MARKET SUMMARY -
Table 6-1: The Global Market for Anti-Infectives by Product Segment, 2007-2015
-
Figure 6-1: The World Market for Anti-Infective Drugs 2007-2015
-
Figure 6-2: The Global Market for Anti-Infectives by Product Segment, 2011
-
Figure 6-3: The Global Market for Anti-Infectives by Product Segment, 2015
More Global Infectious Diseases Reports
2012 World Infectious Disease Testing Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by
Venture Planning Group
This report provides a worldwide overview of the infectious disease testing market environment, structure, size and growth. Includes estimates of the number of laboratories ...
2012 Global Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies by
Venture Planning Group
The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers ...
Global Infectious Disease Treatment Market 2011-2014 by
Infiniti Research Limited
TechNavio’s analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 8.1 percent over the period 2011–2014. One of the key ...
Future Infectious Disease Testing Market: Growth Opportunities, Business Strategies, Market Entry Barriers and Risks by
Venture Planning Group
The report identifies the major opportunities for infectious disease testing instrumentation, reagent kits/test panels, consumables, as well as IT and auxiliary products; proposes design criteria ...
Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast by
Renub Research
Influenza Vaccine Market Overview
Last few years have seen renewed interest in the vaccines market, overcoming the prevailing view that vaccines are a low-margin ...
See all reports like this >>
Share this report
Other tasks Related Markets Infectious Diseases Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
